Literature DB >> 23699668

18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.

Jun Sato1, Yoshimasa Kitagawa, Yutaka Yamazaki, Hironobu Hata, Shozo Okamoto, Tohru Shiga, Masanobu Shindoh, Yuji Kuge, Nagara Tamaki.   

Abstract

UNLABELLED: Hypoxia is a common feature of cancer and a prognostic factor for many types of cancer. (18)F-fluoromisonidazole ((18)F-FMISO) PET can detect tumor hypoxia noninvasively. Hypoxia-inducible factor-1 (HIF-1) is a key player in the transcriptional response to low oxygen tension in many types of cancer. Its activity is mainly dependent on the stability and modification of HIF-1α, which is a composition of HIF-1. However, it is unclear whether (18)F-FMISO PET can identify HIF-1α expression in oral squamous cell carcinoma (OSCC). The present study was performed to elucidate the correlation between (18)F-FMISO PET findings and HIF-1α expression in OSCC.
METHODS: Twenty-three patients (age range, 42-84 y; 15 men, 8 women) with OSCC were enrolled in this study. The T-stages of cancer were T1 in 1 patient, T2 in 9, T3 in 2, and T4a in 11. The N-stages were N0 in 13 patients, N1 in 5, and N2 in 5. Each patient underwent (18)F-FMISO and (18)F-FDG PET before surgery, and the maximum standardized uptake value (SUV max) of both PET studies was measured. HIF-1α expression in the operation materials was evaluated by immunohistochemical staining. The SUV max of both PET studies and HIF-1α findings were compared statistically.
RESULTS: (18)F-FMISO PET detected uptake in the primary site in 14 of the 23 patients (61%). The median SUV max of (18)F-FMISO and (18)F-FDG PET in the primary site was 1.83 (range, 0.8-2.7) and 16.5 (range, 1.0-32.3), respectively. There was a weak significant correlation between (18)F-FMISO and (18)F-FDG PET SUV max (P = 0.02, r = 0.48). HIF-1α expression was clearly detected in 11 of the 23 patients (48%). The (18)F-FMISO PET SUV max was significantly higher in the HIF-1α-positive cases than in the HIF-1α-negative cases (median, 2.1; range, 1.5-2.4, vs. median, 1.6; range, 0.8-2.0, respectively) (P = 0.002). However, there were no significant correlations between (18)F-FDG PET SUV max and HIF-1α expression (median, 21.8; range, 7.7-29.1 vs. 1.0-32.2) (P = 0.06).
CONCLUSION: (18)F-FMISO uptake in the primary site of OSCC indicates a hypoxic environment with HIF-1α expression.

Entities:  

Keywords:  FMISO PET; HIF-1α; hypoxia; oral squamous cell carcinoma

Mesh:

Substances:

Year:  2013        PMID: 23699668     DOI: 10.2967/jnumed.112.114355

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  20 in total

1.  FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis.

Authors:  Akira Watanabe; Norifumi Harimoto; Takehiko Yokobori; Kenichiro Araki; Norio Kubo; Takamichi Igarashi; Mariko Tsukagoshi; Norihiro Ishii; Takahiro Yamanaka; Tadashi Handa; Tetsunari Oyama; Tetsuya Higuchi; Ken Shirabe
Journal:  Int J Clin Oncol       Date:  2019-10-14       Impact factor: 3.402

Review 2.  Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.

Authors:  Helen Cliffe; Chirag Patel; Robin Prestwich; Andrew Scarsbrook
Journal:  Br J Radiol       Date:  2017-01-30       Impact factor: 3.039

3.  Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.

Authors:  Jun Sato; Yoshimasa Kitagawa; Yutaka Yamazaki; Hironobu Hata; Takuya Asaka; Masaaki Miyakoshi; Shozo Okamoto; Tohru Shiga; Masanobu Shindoh; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-28       Impact factor: 9.236

Review 4.  Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.

Authors:  Sonja Stieb; Afroditi Eleftheriou; Geoffrey Warnock; Matthias Guckenberger; Oliver Riesterer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-20       Impact factor: 9.236

Review 5.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 6.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

Review 7.  Imaging for Response Assessment in Cancer Clinical Trials.

Authors:  Anna G Sorace; Asser A Elkassem; Samuel J Galgano; Suzanne E Lapi; Benjamin M Larimer; Savannah C Partridge; C Chad Quarles; Kirsten Reeves; Tiara S Napier; Patrick N Song; Thomas E Yankeelov; Stefanie Woodard; Andrew D Smith
Journal:  Semin Nucl Med       Date:  2020-06-10       Impact factor: 4.446

8.  Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic (18)F-FMISO-Pet-Ct and quantitative histology.

Authors:  Pamela Mena-Romano; Caixia Cheng; Christin Glowa; Peter Peschke; Leyun Pan; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss; Christian P Karger
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

9.  The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.

Authors:  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Shiro Watanabe; Kenji Hirata; Ken-Ichi Nishijima; Keiichi Magota; Katsuhiko Kasai; Rikiya Onimaru; Kazuhiko Tuchiya; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-01       Impact factor: 9.236

Review 10.  Radiolabeled probes targeting hypoxia-inducible factor-1-active tumor microenvironments.

Authors:  Masashi Ueda; Hideo Saji
Journal:  ScientificWorldJournal       Date:  2014-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.